Skip to main content
TipRanks
Go Ultimate75% OFF

Lyell Immunopharma (LYEL) Ratios

163 Followers

Lyell Immunopharma Ratios

LYEL's free cash flow for Q3 2026 was $-34.63M. For the 2026 fiscal year, LYEL's free cash flow was decreased by $-66.00K and operating cash flow was $-34.57M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio5.287.0616.0717.5913.40
Quick Ratio5.287.0616.0717.5913.40
Cash Ratio1.221.964.223.346.29
Solvency Ratio-2.86-2.99-2.25-1.58-1.20
Operating Cash Flow Ratio-3.04-3.02-4.74-4.58-2.70
Short-Term Operating Cash Flow Coverage0.000.000.000.000.00
Net Current Asset Value$ 169.09M$ 271.56M$ 459.61M$ 546.99M$ 428.67M
Leverage Ratios
Debt-to-Assets Ratio0.150.120.080.070.06
Debt-to-Equity Ratio0.210.150.100.080.07
Debt-to-Capital Ratio0.170.130.090.080.07
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.371.281.151.131.21
Debt Service Coverage Ratio0.000.000.000.000.00
Interest Coverage Ratio0.000.000.000.000.00
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share2.984.515.035.485.59
Net Debt to EBITDA0.030.230.360.331.12
Profitability Margins
Gross Profit Margin-31952.78%100.00%100.00%100.00%100.00%
EBIT Margin-762355.56%-361104.92%-190006.15%-220.89%-2016.68%
EBITDA Margin-730302.78%-328922.95%-174429.23%-199.61%-1888.75%
Operating Profit Margin-566038.89%-588122.95%-190006.15%-220.89%-2016.68%
Pretax Profit Margin-762355.56%-562285.25%-180486.15%-216.24%-2349.47%
Net Profit Margin-762355.56%-562285.25%-180486.15%-216.24%-2349.47%
Continuous Operations Profit Margin-762355.56%-562285.25%-180486.15%-216.24%-2349.47%
Net Income Per EBT100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT134.68%95.61%94.99%97.89%116.50%
Return on Assets (ROA)-80.71%-69.88%-31.28%-19.53%-22.19%
Return on Equity (ROE)-110.57%-89.60%-35.82%-21.98%-26.91%
Return on Capital Employed (ROCE)-70.11%-82.08%-34.52%-20.77%-19.87%
Return on Invested Capital (ROIC)-67.99%-80.61%-34.22%-20.67%-19.85%
Return on Tangible Assets-80.71%-69.88%-31.28%-19.53%-22.19%
Earnings Yield-52.16%-204.96%-48.19%-21.36%-13.32%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover3.990.000.000.000.00
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.510.06
Asset Turnover0.000.000.000.090.01
Working Capital Turnover Ratio0.000.000.000.140.02
Cash Conversion Cycle-91.510.000.000.000.00
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding91.510.000.000.000.00
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-8.78-12.42-13.04-13.72-10.40
Free Cash Flow Per Share-8.82-12.46-13.26-15.69-15.80
Dividend Paid and CapEx Coverage Ratio-192.34-349.99-60.94-6.98-1.93
Capital Expenditure Coverage Ratio-192.34-349.99-60.94-6.98-1.93
Operating Cash Flow Coverage Ratio-2.94-2.75-2.59-2.50-1.86
Operating Cash Flow to Sales Ratio-4167.33-2662.20-1259.18-2.00-11.85
Free Cash Flow Yield-28.66%-97.32%-34.17%-22.61%-10.21%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-1.92-9.77-2.08-4.68-7.51
Price-to-Sales (P/S) Ratio14614.512743.403745.4410.12176.41
Price-to-Book (P/B) Ratio2.120.440.741.032.02
Price-to-Free Cash Flow (P/FCF) Ratio-3.49-1.03-2.93-4.42-9.80
Price-to-Operating Cash Flow Ratio-3.51-1.03-2.97-5.06-14.88
Price-to-Earnings Growth (PEG) Ratio-0.00-0.24-0.080.17-0.34
Enterprise Value Multiple-1.97-0.60-1.78-4.74-8.22
Enterprise Value516.94M120.72M404.43M801.52M1.65B
EV to EBITDA-1.97-0.60-1.78-4.74-8.22
EV to Sales14359.321978.993110.989.46155.19
EV to Free Cash Flow-3.43-0.74-2.43-4.14-8.62
EV to Operating Cash Flow-3.45-0.74-2.47-4.73-13.09
Tangible Book Value Per Share14.5229.2852.1967.4576.61
Shareholders’ Equity Per Share14.5229.2852.1967.4576.61
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share0.000.000.016.850.88
Net Income Per Share-16.06-26.23-18.70-14.82-20.62
Tax Burden1.001.001.001.001.00
Interest Burden1.001.560.950.981.17
Research & Development to Revenue4407.642813.161407.271.8813.02
SG&A to Revenue1253.75853.13515.251.398.36
Stock-Based Compensation to Revenue1161.92543.34362.180.005.84
Income Quality0.550.470.700.930.50

Currency in USD